. 2018 Aug 4;35(9):1333–1355. doi: 10.1007/s12325-018-0759-0

Table 2.

Summary of compliance rates with TNFi at 1 year reported across all identified studies, by geographic region

Country	Data source	Time point	Treatment
Country	Data source	Time point	Adalimumab	Etanercept	Infliximab	Golimumab
USA	Registries	1 year [82]	–	–	65.7% (CD)	–
	Claims data	1 year [50, 81, 99]	70.0%^a (RA)	32%^a (RA) 61.2%^a (RA)	43%^a (RA) 73% (CD)	81.2^a (RA)
	Medical records	1 year [100]	–	–	96% (CD)^b	–

The data included in the table include the results from studies reporting data from 1 through 7 years of anti-TNF use. Supplementary Table 1 provides a full list of studies identified, including those reporting values from 0–1 year

CD Crohn’s disease, RA rheumatoid arthritis

^aBased on proportion of days covered (PDC) ≥ 0.80

^bBased on 4% appointments classified as ‘no show’